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Abstract
Background: Aberrant ErbB receptor signaling is associated with various types of malignancies. g-Tocotrienol is a
member of the vitamin E family of compounds that displays potent anticancer activity that is associated with
suppression in ErbB receptor phosphorylation and mitogenic signaling. Erlotinib and gefitinib are tyrosine kinase
inhibitors that block ErbB1 receptor activation, whereas trastuzumab is a monoclonal antibody that has been
designed to specifically inhibit ErbB2 receptor activation. However, the clinical effectiveness of these agents have
been disappointing because of cooperation between different ErbB family members that can rescue cancer cells
from agents directed against a single ErbB receptor subtype. It was hypothesized that targeting multiple ErbB
receptor subtypes with combined treatment of g-tocotrienol and ErbB receptor inhibitors would provide greater
anticancer effects than monotherapy targeting only a single ErbB receptor subtype.
Methods: Highly malignant mouse +SA mammary epithelial cells were maintained in culture on serum-free
defined media containing 10 ng/ml EGF as a mitogen. Cell viability wase determined by MTT assay, whereas
Western blot and immunofluorescent staining was used to determine treatment effects on ErbB receptor subtype
level and activation. Treatment-induced apoptosis was determined using annexin V staining and Western blot
analysis of cleaved caspase-3 and PARP levels.
Results: Treatment with 3.5 μM g-tocotrienol, 0.5 μM erlotinib or 1.0 μM gefitinib alone, significantly inhibited +SA
tumor cell growth. Combined treatment with subeffective doses of erlotinib (0.25 μM) or gefitinib (0.5 μM) with
subeffective doses of g-tocotrienol (0.5-3.0 μM) significantly inhibited the growth and induced apoptosis in a dose-
responsive manner. Trastuzumab treatment alone or in combination had no effect on +SA cell growth and
viability. Combined treatment of g-tocotrienol with erlotinib or gefitinib also cause a large decrease in ErbB3, ErbB4,
and to a lesser extent ErbB2 receptor levels, and EGF-dependent ErbB2-4 tyrosine phosphorylation (activation), but
had no effect on ErbB1 receptor levels or activation.
Conclusion: Combination treatment of g-tocotrienol with specific ErbB receptor inhibitors is more effective in
reducing mammary tumor cell growth and viability than high dose monotherapy, suggesting that targeting
multiple ErbB receptors with combination therapy may significantly improve the therapeutic response in breast
cancer patients.
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g-Tocotrienol is a member of the vitamin E family of
compounds that displays potent anticancer activity at
treatment doses that have little or no effect on normal
cell function or viability [1-4]. Studies have shown that
the growth inhibitory effects of g-tocotrienol result from
a suppression in EGF-dependent ErbB3 receptor activa-
tion and subsequent reduction in phosphatidylinositol 3-
kinase (PI3K)/Akt mitogenic signaling [5]. EGF-recep-
tors belong to the HER (human) or ErbB (mouse) family
of receptor tyrosine kinases and include four members
classified as ErbB1-4. Various EGF-like receptor ligands
bind to and activate ErbB1, ErbB3 and ErbB4 receptors,
leading to the formation of receptor homo- and hetero-
dimers [6-8]. Receptor dimerization allows for transpho-
sphorylation of specific tyrosine residues located on the
intracellular domain which are required for substrate
interaction and downstream activation of mitogenic sig-
naling pathways [6,9]. Although the ErbB2 receptors
lack a ligand binding site and the ErbB3 receptor has no
tyrosine kinase activity, these receptors can initiate sig-
nal transduction by undergoing homo- or heterodimeri-
zation [10,11] and are particularly potent in activating
PI3K/Akt and Ras/mitogen activated protein kinase
(MAPK) mitogenic signaling pathways, and elevated
PI3K/Akt and MAPK activity is associated with
advanced tumor progression and poor prognosis in
breast cancer patients [6,9,12,13].
ErbB receptors are expressed in a wide range of cell
types and play an important role in normal cell prolif-
eration and survival. However, aberrant ErbB receptor
signaling is often associated with the development of
various types of human malignancies. Two important
strategies have been developed to target ErbB receptors
in cancer. One strategy uses monoclonal antibodies
directed towards the extracellular domain of ErbB
receptors, while the other strategy uses small molecule
tyrosine kinase inhibitors (TKIs) that compete with ATP
for binding to the kinase domain of the receptor. Erloti-
nib and gefitinib are TKIs that compete with ATP for
binding to the intracellular catalytic domain of ErbB1
receptor, and reversibly inhibit the phosphorylation and
signal transduction events associated with ErbB1 recep-
tor activation [14]. Trastuzumab is a monoclonal anti-
body that has been designed to specifically inhibit the
activation of ErbB2 receptor [15].
Unfortunately, the clinical usefulness of agents that
target only a single ErbB receptor subtype has been lim-
ited due to cooperation between the different ErbB
family members that leads to the formation of heterodi-
mers that are able to circumvent and rescue cancer cells
from the inhibitory effects of these agents [9,16-18].
However, the therapeutic efficacy of ErbB receptor
inhibitors can be improved by interfering with the coop-
eration among different ErbB receptor family members
[19,20]. Since previous studies showed that the antiproli-
ferative effects of g-tocotrienol are associated with sup-
pression in ErbB3 receptor activation and mitogenic
signaling, studies were conducted targeting multiple
ErbB receptors with combined treatment of g-tocotrie-
nol with ErbB receptor inhibitors to determine if com-
bined treatment provided a greater anticancer response
as compared to monotherapy that targets only a single
ErbB receptor subtype.
Methods
Reagents and Antibodies
All reagents were purchased from Sigma Chemical Co.
(St Louis, MO.), unless otherwise stated. Antibodies for
ErbB1 (# 2232), phospho-ErbB1 (Tyr 1173) (# 4407),
ErbB2 (# 2242), phospho-ErbB2 (Tyr 877) (# 2241),
ErbB3 (# 4754), phospho-ErbB3 (Tyr 1289) (# 4791),
phospho-ErbB4 (Tyr 1284) (# 4757), caspase-3 (# 9662),
cleaved caspase-3 (# 9661), PARP (# 9542), and cleaved
PARP (# 9544), for use in Western blot analysis were
purchased from Cell Signaling Technology (Beverly,
MA). ErbB4 receptor antibody (# RB-284-P0) was pur-
chased from Neomarkers (Fremont, CA). Antibodies for
ErbB1 (sc-03), ErbB2 (sc-284), ErbB3 (sc-285), ErbB4
(sc-883), phospho-ErbB2 (sc-12352), phospho-ErbB4
(sc-33040) and their respective blocking peptides were
purchased from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA) for immunofluorescence studies. Goat anti-
rabbit (NEF812001EA) and goat anti-mouse
(NEF822001EA) secondary antibodies were obtained
from PerkinElmer Biosciences (Boston, MA). Polyclonal
anti-tubulin antibody (CP06) was purchased from Cal-
biochem (San Diego, CA). Rhodamine red conjugated
goat anti-rabbit secondary antibody (R6394) was pur-
chased from Molecular Probes (Invitrogen Corporation,
Carlsbad, CA).
Cell Line and Culture Conditions
Experiments conducted in the present study represent a
logical continuation of previous studies that have exten-
sively characterized the antiproliferative and apoptotic
effects of g-tocotrienol in the highly malignant +SA
mammary epithelial cell line [21]. The neoplastic +SA
cell line was derived from a mammary adenocarcinoma
that developed spontaneously in a BALB/c female
mouse. The +SA cell line is characterized as being
highly malignant, estrogen-independent, and displays
anchorage-independent growth when cultured in soft
agarose gels [22,23]. Cell culture and experimental pro-
cedures have been previously described in detail [2,3,24].
Briefly, +SA cells were maintained in serum-free defined
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Page 2 of 13DMEM/F12 media (supplemented with 5 mg/ml BSA,
10 μg/ml insulin, 10 μg/ml transferrin, 100 U/ml soy-
bean trypsin inhibitor, 1 μg/ml d-a-tocopherol, 100 U/
ml penicillin, 0.1 mg/ml streptomycin, and 10 ng/ml
EGF) at 37°C in an environment of 95% air and 5% CO2
in humidified incubator. For plating cells at the start of
each experiment, cells were isolated with trypsin, pel-
leted by centrifugation, and then resuspended in serum-
free defined medium, and counted by hemocytometer.
Cells were plated at a density of 5 × 10
4 cells/well in
24-well culture plates (growth studies) or 2 × 10
5 cells/
well in 6-well culture plates (immunofluorescence stu-
dies) or 1 × 10
6 cells/100-mm culture plates (all other
studies) and allowed to attach in serum-free defined
media for 24 h.
Experimental Treatments
g-Tocotrienol was generously provided by First Tech
International Ltd. (Hong Kong), erlotinib and trastuzu-
mab were provided as a gift by Genentech (San Fran-
cisco, CA), and gefitinib was kindly provided by
AstraZeneca (Cheshire, UK). The highly lipophilic g-
tocotrienol was suspended in a solution of sterile 10%
BSA as described previously [2,24]. Briefly, an appropri-
ate amount of g-tocotrienol was dissolved in 100 μlo f
100% ethanol, and then added to a small volume of ster-
ile 10% BSA in water and incubated overnight at 37°C.
This g-tocotrienol/BSA solution was then used to pre-
pare various concentrations of treatment media. All con-
trol and treatment media had a final concentration of 5
mg/ml BSA, and ethanol was added to all treatment
media such that the final concentration was the same in
all treatment groups with in a given experiment and was
always less than 0.1%. Stock solutions of erlotinib and
gefitinib were prepared in DMSO and added to the cul-
ture medium so that the concentration of DMSO never
exceeds 0.1%. Trastuzumab was dissolved in sterile
water.
Measurement of Viable Cell Number
+SA cell number was measured by 3-(4, 5-dimethylthia-
zol-2yl)-2,5-diphenyl tetrazolium bromide (MTT) colori-
metric assay as described previously [2,5,24-26]. After
the end of the treatment period, control and treatment
media were replaced with fresh serum-free control
defined media containing 0.41 mg/ml MTT and
returned to the incubator for a period of 4 h. After
incubation, the media was removed and MTT crystals
were dissolved in 1 ml of isopropanol. The optical den-
sity of each sample was measured at 570 nm on a
microplate reader (SpectraCount, Packard BioScience
Company, Meriden, CT) zeroed against a blank pre-
pared from cell free medium. The number of cells per
well was calculated against a standard curve prepared by
plating known concentrations of cells, as determined by
hemocytometer, in triplicate at the start of each
experiment.
Western Blot Analysis
After the end of the treatment period, cells in the var-
ious treatment groups were isolated with trypsin, and
whole cell lysates were prepared and dissolved in
Laemmli buffer as previously described, [5,24,26] and
protein concentration in each sample was determined
by using BioRad protein assay kit (BioRad, Hercules,
CA). Equal amounts of protein from each sample (25-40
μg/lane) in a given experiment was loaded on SDS-poly-
acrylamide minigels and electrophoresed through 5%-
15% resolving gel. Each gel was then equilibrated in
transfer buffer and transblotted for 12-16 h at 4°C at
30 mV to PVDF membranes (Dupont, Boston, MA)
according to method of Towbin [27]. The membranes
were blocked with 2% BSA in 10 mM Tris HCl contain-
ing 50 mM NaCl and 0.1% Tween 20 pH 7.4 (TBST)
and incubated with specific primary antibodies against
total and phosphorylated ErbB1-4 receptors, caspase-3,
cleaved caspase-3, PARP, and cleaved PARP in TBST
containing 2% BSA for 2 h. Membranes were then
rinsed 5 times with TBST for 25 min followed by incu-
bation with horseradish peroxide conjugated goat anti-
rabbit or goat anti-mouse antibody in TBST containing
2% BSA for 1 h. Blots were then rinsed 5 times with
TBST buffer and the protein bands were then visualized
by chemiluminescence according to the manufacturer’s
instructions (Pierce, Rockford, IL). The visualization of
a-tubulin was used to confirm that there was equal
sample loading in each lane.
Measurement of Annexin V Staining
Analysis of annexin V binding in each treatment group
was determined using Annexin V-FITC Apoptosis
Detection Kit I (BD PharMingen, San Diego, CA.) as
described previously [28]. Briefly, cells in each treatment
group were harvested and resuspended in annexin V
binding buffer at a concentration of 1 × 10
6 cells/ml.
Later, 5 μl of annexin V and 5 μl of propidium iodide
was added to 100 μl of the suspension in triplicate and
i n c u b a t e di nd a r kf o r1 5m i na tr o o mt e m p e r a t u r e .
Samples were then diluted to 500 μl with binding buffer
and analyzed by flow cytometer (FACS-Calibur, BD
Biosciences, San Jose, CA). Data was processed using
CellQuest software (BD Biosciences).
Immunofluorescent Staining
Neoplastic +SA cells in various treatment groups were
rinsed twice with 0.05 M Tris buffered saline (TBS) pH
7.6, fixed with methanol previously cooled to -20°C and
blocked with 2% goat serum in TBS for 30 min. Cells
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against ErbB1-4, phospho-ErbB2 or phospho-ErbB4
receptors overnight at 4°C in 2% goat serum in TBS.
After washing the cells 5 times with TBS, cells were
incubated in dark with rhodamine conjugated goat anti-
rabbit antibody in 2% goat serum in TBS. After 5 final
washings, cells were embedded in Vectashield Mounting
Medium (Vector Laboratories Inc., Burlingame, CA).
Staining was examined by Nikon ECLIPSE TE2000-U
microscope (Nikon Instruments Inc., Melville, NY)
coupled with CoolSNAP cf CCD camera (Roper Scienti-
fic Inc, Photometrics, Tucson, AZ). Digital images were
captured using Metamorph software (Universal Imaging
Corporation). Gray scale images thus obtained were
pseudo-colored and the fluorescence observed for each
ErbB receptor was assigned a different color. ErbB1, 2, 3
and 4 receptors were assigned blue, green, red and yel-
low colors respectively. The specificity of each antibody
used in the immunofluorescent staining was verified
using a blocking peptide that corresponded to the epi-
tope recognized by the primary antibody.
Statistical Analysis
Differences among various treatment groups in growth
studies were determined by analysis of variance followed
by Dunnett’s t test. Differences were considered statisti-
cally significant at a value of P < 0.05. The level of inter-
action between the ErbB receptor inhibitors and g-
tocotrienol was determined by combination index (CI)
analysis as described previously [26]. The combination
index (CI) is a quantitative representation of pharmaco-
logical interaction between two drugs. The CI value <1,
1 and >1 indicate synergistic, additive and antagonistic
effects respectively. The CI values are calculated as
follows
CI =+ [] Xc X Tc T //
X and T stand for the concentrations of ErbB inhibitor
and g-tocotrienol respectively, that induce 50% cell
growth inhibition; Xc and Tc are the concentrations of
ErbB inhibitor and g-tocotrienol that induce 50% cell
growth inhibition when used in combination as deter-
mined by nonlinear regression curve fit analysis using
GraphPad Prism 5 software.
Results
Antiproliferative effects of g-tocotrienol, erlotinib,
gefitinib and trastuzumab
Treatment effects on the growth of highly malignant
+SA mouse mammary epithelial cells over a 4-day cul-
ture period are shown in Figure 1. Treatment with 3.5
μM g-tocotrienol, 0.5-3 μM erlotinib, or 1-3 μM gefiti-
nib significantly inhibited EGF-dependent +SA cell
growth as compared to the vehicle treated control
group. However, treatment with 0-250 μg/ml trastuzu-
mab had no effect on +SA cell growth (Figure 1).
Antiproliferative effects of combined g-tocotrienol
treatment with erlotinib, gefitinib or trastuzumab
In combination studies, a range of subeffective doses of
g-tocotrienol (0.5-3 μM) were combined with subeffec-
tive doses of erlotinib (0.25 μM), gefitinib (0.5 μM) or
trastuzumab (20 μg/ml), to determine treatment effect
on +SA cell growth over a 4-day culture period. Figure
2 shows that treatment with 3 μM g-tocotrienol, 0.25
μMe r l o t i n i b ,0 . 5μM gefitinib or 20 μg/ml trastuzumab
had no significant effect on +SA cell growth as com-
pared to vehicle-treated controls (Figure 2). However,
combined treatment with similar doses of erlotinib or
gefitinib with a range of subeffective doses of g-tocotrie-
nol (0.5-3 μM) induced a significant reduction in the
EGF-dependent +SA cell growth (Figure 2). In contrast,
combined treatment of 20 μg/ml trastuzumab with 0.5-3
μM g-tocotrienol had no effect on +SA cell growth (Fig-
u r e2 ) .T h eC Iv a l u e sf o rt h ec o m b i n a t i o no fe r l o t i n i b
with g-tocotrienol (0.96) and gefitinib with g-tocotrienol
(0.91) is <1 and indicate a synergistic interaction of
these drug combinations. It was not possible to calculate
the CI value for the combination of trastuzumab with g-
tocotrienol because the dose at with the trastuzumab
induced 50% growth inhibition could not be determined
using the doses tested in the current study. Figure 3
shows photomicrographs of +SA cells in the various
treatment groups described in Figure 2. Treatment of
erlotinib or gefitinib in combination with g-tocotrienol
resulted in a suppression in +SA cell growth and a slight
change in cellular morphology from a flat to a more
e l o n g a t e da n dr o u n di ns h a p e ,i ndicating cellular stress
and the initiation of apoptosis (Figure 3).
Apoptotic effects of Combined g-Tocotrienol Treatment
with Erlotinib, Gefitinib or Trastuzumab
The effects of combined g-tocotrienol treatment with
erlotinib, gefitinib or trastuzumab on cleaved caspase-3
(activated) and cleaved PARP levels (markers for apop-
tosis) in +SA cells following a 4-day culture period are
shown in Figure 4. Western blot analysis showed that
combined g-tocotrienol treatment with erlotinib or gefi-
tinib, but not trastuzumab, increased the levels of
cleaved caspase-3 and cleaved PARP.
Figure 5 shows the effect of the various treatments on
annexin V staining in +SA cells following a 4-day cul-
ture period. Viable cells in the control group displayed
very low annexin V staining and they appear in the M1
region of the histogram (Figure 5). When the cells
undergo apoptosis, there will be an increase in the cells
staining positive to annexin V and results in the shift of
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0.25 μM erlotinib, 0.5 μM gefitinib, 20 μg/ml trastuzu-
mab, 3 μM g-tocotrienol and the combination of 20 μg/ml
trastuzumab and 3 μM g-tocotrienol treated groups more
than 96% of the cells appear in the M1 region where as
the percentage of cell appearing in the M1, M2 regions in
combined g-tocotrienol and erlotinib or gefitinib is
48.03%, 51.48% and 36%, 63.24% respectively as deter-
mined by the CellQuest software. These results indicate
that combined g-tocotrienol treatment with erlotinib or
gefitinib, but not trastuzumab, increased the percentage of
cells appearing in M2 region (Figure 5)
EGF-induced ErbB Receptor Phosphorylation
Western blot analysis showed that following exposure to
EGF, there was a gradual decrease in the total levels of
ErbB1, ErbB3 and ErbB4 receptors over a 60 min time
period, while ErbB2 receptor levels showed a transient
increase and then decrease in levels following EGF
exposure (Figure 6). EGF exposure resulted in an
increase in tyrosine phosphorylation (activation) in all
ErbB receptor family members (ErbB1-4), with maximal
phosphorylation observed 10 min after EGF exposure
f o l l o w e db yas u b s e q u e n td e c r e a s ei nE r b B 1 - 4r e c e p t o r
tyrosine phosphorylation, reflecting the internalization
and degradation of ErbB1-4 heterodimer receptor com-
plexes following EGF-induced activation (Figure 6).
Figure 7 shows immunofluorescence images of total
ErbB1-4 receptors, phospho-ErbB2 and phospho-ErbB4
receptors, before (Figure 7, left) and 10 min after stimu-
lation with EGF (Figure 7, right). Results showed that
the fluorescent intensities of phospho-ErbB2 and phos-
pho-ErbB4 receptors increased after 10 min of EGF
exposure. Fluorescent detection of phospho-ErbB1 and
phospho-ErbB3 receptors could not be performed
because of the unavailability of specific mouse reactive
primary antibody for immunofluorescent application.
Immunofluorescence studies show that ErbB1, ErbB2,
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Figure 1 Antiproliferative effects of g-tocotrienol, erlotinib, gefitinib, and trastuzumab on neoplastic +SA mammary epithelial cell
growth. Cells were plated at a density of 5 × 10
4 cells per well (6 replicates/group) in 24-well plates and exposed to their respective treatments
for a 4-day period. Viable cell number was determined by MTT colorimetric assay and indicated as percentage of control. Each bar represents
the mean ± SEM in each treatment group and is representative of three independent experiments. *P < 0.05 as compared to the vehicle treated
controls.
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Page 5 of 13phospho-ErbB2 and ErbB4 receptors are primarily
located on the cell surface, ErbB3 receptors are primar-
ily located in the nucleus, while phospho-ErbB4 recep-
tors are relatively evenly distributed between both the
nucleus and cell surface in neoplastic +SA mammary
epithelial cells (Figure 7).
Effects of combined g-tocotrienol treatment with erlotinib
or gefitinib on ErbB Receptor Levels and Phosphorylation
Western blot analysis showed that subeffective doses of
erlotinib or gefitinib given in combination with subeffec-
tive dose of g-tocotrienol resulted in a relatively large
reduction in EGF-induced ErbB3, ErbB4, and to a lesser
extent a decreased in ErbB2 receptor tyrosine phosphor-
ylation as compared to untreated controls (Figure 8,
right). Similar treatment was found to have no effect on
the level of total ErbB1 or EGF-induced ErbB1 receptor
tyrosine phosphorylation (Figure 8, right). Treatment
with either g-tocotrienol, erlotinib or gefitinib alone was
not found to cause a change in total or EGF-induced
ErbB1-4 receptors tyrosine phosphorylation levels (Fig-
ure 8, right). Combination treatment of g-tocotrienol
with erlotinib or gefitinib also caused a reduction in
total levels of ErbB2, ErbB3 and ErbB4 receptors, as
compared to untreated controls (Figure 8, left).
Figure 9 shows the immunofluorescent images of ErbB
receptors after a 4-day treatment exposure. There were
fewer cells in all the combination treatment groups,
reflecting the growth inhibitory and apoptotic effects of
these treatments (Figure 9). The fluorescent images
showed that combined treatment of g-tocotrienol with
erlotinib or gefitinib caused a reduction in fluorescence
intensities of the total and/or phosphorylated ErbB2-4
receptors, but not ErbB1 receptors. Interestingly, it was
found that combined treatment of g-tocotrienol with
erlotinib or gefitinib resulted in a large reduction in
fluorescence intensity in the membrane, but only a
moderate reduction in the nuclear levels of phospho-
ErbB4 in these cells (Figure 9). Fluorescent detection of
phospho-ErbB1 and phospho-ErbB3 receptors could not
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Figure 2 Effects of various subeffective doses of g-tocotrienol (gT
3) when given alone or in combination with subeffective dose of
erlotinib (E), gefitinib (G), or trastuzumab (T) on neoplastic +SA mammary epithelial cell growth. Cells were plated at a density of 5 ×
10
4 cells per well (6 replicates/group) in 24-well plates and exposed to respective control and treatment serum-free defined media for a 4-day
period. Viable cell number was determined by MTT colorimetric assay and indicated as percentage of control. Each bar represents the mean ±
SEM in each treatment group and is representative of three independent experiments. *P < 0.05 as compared to the vehicle treated controls.
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Page 6 of 13be performed because of the unavailability of specific
mouse reactive primary antibody for immunofluorescent
application.
Discussion
Results in this study demonstrate that combined low
dose treatment of g-tocotrienol with erlotinib or gefiti-
nib significantly enhanced the antiproliferative and
apoptotic effects of these treatments as compared to
monotherapy alone in neoplastic +SA mammary epithe-
lial cells. Studies also show e dt h a tc o m b i n e dt r e a t m e n t
with low doses of these agents caused suppression in
ErbB3, ErbB4, and to a lesser extent, ErbB2 receptor
activation in +SA cells. In contrast, trastuzumab treat-
ment had no effect on +SA cell growth when given
alone or in combination with g-tocotrienol.
Vitamin E is a generic term that represents a family of
c o m p o u n d st h a ti sf u r t h e rd i v i d e di n t o2s u b g r o u p s
called tocopherols and tocotrienols. There are 4 natural
isoforms exist in each subgroup based on the degree of
chromane ring methylation and are classified as a, b, g
and δ tocopherol or tocotrienol [21]. Previous studies
have shown that g-tocotrienol inhibited the growth of
+SA mammary epithelial cells at doses that had little or
no effect on the normal cell growth [1-3]. Studies have
also shown that g-tocotrienol inhibits the growth of
Figure 3 Photomicrographs of neoplastic +SA mammary epithelial cells in culture treated with a subeffective dose of g-tocotrienol
(gT
3) alone or in combination with a subeffective dose of erlotinib (E), gefitinib (G), or trastuzumab (T). Cells were plated at a density of
5×1 0
4 cells (Day 0) per well (6 replicates/group) in 24-well plates and exposed to respective control and treatment serum-free defined media
for a 4-day period. Magnification is 100×.
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Page 7 of 13human breast cancer cell lines [29]. Recommended safe
dose limits in humans for the various tocotrienol iso-
forms for human is 200-1000 mg/day and treatment
with these doses has been reported to be devoid of
adverse side effects [30]. However, very high dose of
tocotrienols were reported to inhibit the platelet aggre-
gation and increase clotting time in patients [31]. Treat-
ment doses of g-tocotrienol used in the present study
are physiologically relevant based on serum concentra-
tions of tocotrienols that were found to ranged between
2-4 μM in individuals given a single oral dose of mixed
tocotrienols (300 mg) under fed or fasted conditions
[32]. The present study shows that treatment with 0.5-3
μMo fe r l o t i n i b ,1 - 3μM gefitinib, or 3.5 μM g-tocotrie-
nol significantly inhibited EGF-dependent +SA cell
growth. Treatment with 0-250 μg/ml trastuzumab alone
or in combination with 0-3 μM g-tocotrienol had no
effect on +SA cell growth or viability. The exact reason
why trastuzumab was ineffective in suppressing +SA cell
growth is presently unknown, but may be related to the
fact that not all the breast cancer cells are sensitive to
the trastuzumab treatment. Previous investigations have
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Figure 4 Western blot analysis of g-tocotrienol (g T
3), erlotinib (E), gefitinib (G), or trastuzumab (T) treatment effects given alone and
in combination on the relative levels of cleaved caspase-3, caspase-3, cleaved PARP and PARP in neoplastic +SA mammary epithelial
cells after a 4-day incubation period. +SA mammary tumor cells were plated at a density of 1 × 10
6 cells/100 mm culture dish and incubated
with control or treatment defined media over a period of 4-days. Afterwards, whole cell lysates (30 μg) from different treatment groups were
prepared for subsequent separation by PAGE followed by Western blot analysis. Each Western blot is a representative image of data obtained for
experiments that were repeated at least three times.
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Page 8 of 13shown that trastuzumab is effective only in cancer cells
that are primarily dependent on oncogenic HER/ErbB2
receptor mitogenic signaling [33] whereas other studies
using the NIH3T3-HER2 mouse model reported that
cancer cells can be ErbB2-dependent, yet still display
resistance to trastuzumab treatment [33].
Treatment with 3 μM g-tocotrienol, 0.25 μMe r l o t i n i b ,
or 0.5 μM gefitinib alone had no effect on +SA cell growth
or viability, whereas combined treatment with these agents
significantly inhibited +SA cell growth and initiated apop-
tosis, as evidenced by a large increase in annexin V stain-
ing and elevations in cleaved caspase-3 and PARP in these
cells. Previous studies have shown that treatment with 10-
20 μM g-tocotrienol was required to initiate apoptosis in
+SA cells [2]. Similarly, erlotinib and gefitinib have also
been shown to induce apoptosis, but at much greater
Figure 5 Effects of combined g-tocotrienol (gT
3), erlotinib (E), gefitinib (G), or trastuzumab (T) treatment on positive annexin V
staining in +SA cells after a 4-day incubation period. +SA mammary tumor cells were plated at a density of 1 × 10
6 cells/100-mm culture
dish and incubated with control or treatment media over a 4-day period. Afterwards, cells were isolated with trypsin, and 1 × 10
6 cells/group in
triplicate were stained with annexin V, and then analyzed by flow cytometry. Viable cells display very low annexin V staining and appear in the
marker 1 (M1) region, whereas cells undergoing apoptosis show very high annexin V staining and appear in the marker 2 (M2) region of the
histogram.
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Figure 6 Total ErbB and phosphorylated ErbB (activation) receptor levels in neoplastic +SA mammary epithelial cells. +SA mammary
tumor cells were initially plated a density of 1 × 10
6 cells/100 mm culture dish. Afterwards, cells were incubated overnight in mitogen-free
media. Cells in all treatment groups were then stimulated with 100 ng/ml EGF for 0-60 min. Following treatment exposure, whole cell lysates
were prepared and then subjected to PAGE followed by Western blot analysis for total and phosphorylated (active) ErbB receptor levels. Each
Western blot is a representative image of data obtained for experiments that were repeated at least three times.
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Page 9 of 13doses (≥ 1 μM) than those used in the present study
[34-36]. Since g-tocotrienol has been shown to induce cas-
pase-3 cleavage and apoptosis through the activation of
caspase-8 (extrinsic pathway) [25], and erlotinib and gefiti-
nib where shown to induce caspase-3 cleavage and apop-
tosis through the activation of caspase-9 (intrinsic
pathway) [35,36], it is possible that apoptosis in the com-
bined treatment groups may be mediated by the activation
of both the intrinsic and extrinsic apoptotic pathways.
Additional studies are required to determine the exact
mechanism initiating apoptosis in the combination treat-
ment groups.
Initial characterization of ErbB receptors in neoplastic
+SA mammary epithelial cells showed that ErbB1-4 recep-
tors are expressed in these cells and display tyrosine phos-
phorylation within 5-10 min following EGF exposure. In
ErbB1
ErbB2
ErbB3
ErbB4
Phospho-ErbB2
Phospho-ErbB4
Unstimulated cells EGF stimulated cells
Figure 7 Immunofluorescent staining of ErbB1-4 receptors, phospho-ErbB2 and phospho-ErbB4 receptors. +SA mammary tumor cells
were initially plated at a density of 2 × 10
5 cells/well in 6-well plates (3 replicates/group) and allowed to attach to the plates followed by
incubation in mitogen-free media overnight. Afterwards, cells were stimulated with 100 ng/ml EGF for 10 min. The cells were fixed with
methanol and incubated with primary antibody directed against specific ErbB receptors, and then incubated with rhodamine conjugated
secondary antibody, as described in the Methods section. Magnification is 200×.
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Figure 8 Western blot analysis of total and phosphorylated ErbB receptor levels treated with g-tocotrienol (gT
3), erlotinib (E) or
gefitinib (G) either alone or in combination. +SA mammary tumor cells were plated at a density of 1 × 10
6 cells/100-mm culture dish and
treated with control or treatment serum-free defined media containing EGF as mitogen. After a 4-day incubation period, whole cell lysates were
subjected to PAGE followed by Western blot analysis for total and phosphorylated (active) ErbB receptor levels. Each Western blot is a
representative example of data obtained for experiments that were repeated at least three times.
Figure 9 Immunofluorescent staining of ErbB1-4 receptors, phospho-ErbB2 and phospho-ErbB4 receptors in +SA cells after treatment
with, g-tocotrienol (gT
3), erlotinib (E), gefitinib (G), alone or in combination. +SA mammary tumor cells were plated at a density of 2 × 10
5
cells per well in 6 well plate (3 replicates/group) and incubated with control or treatment media for 4 days. The cells were then fixed with
methanol and incubated with primary antibody directed against specific ErbB receptors followed by rhodamine conjugated secondary antibody,
as described in the Methods section. Magnification is 200×.
Bachawal et al. BMC Cancer 2010, 10:84
http://www.biomedcentral.com/1471-2407/10/84
Page 11 of 13addition, total ErbB1-4 receptors levels displayed a gradual
decrease between 30-60 min following EGF exposure due
to the growth factor-induced receptor endocytosis and
degradation. Combined treatment with subeffective doses
of g-tocotrienol and subeffective doses of erlotinib or gefi-
tinib caused a large suppression in ErbB3 and ErbB4
receptor phosphorylation (activation). These findings are
of particular interest because elevations in ErbB3 and
ErbB4 receptor expression are associated with poor patient
prognosis in various types of cancers [37,38]. Previous stu-
dies have also shown that ErbB3 receptor heterodimers
are more oncogenic and stable, and suppression of ErbB3
receptor tyrosine phosphorylation greatly reduces the
tumor cell proliferation and growth [37-39]. These find-
ings suggest that combination therapy with agents that
target multiple ErbB receptors effectively interferes with
the heterodimer cooperation that exists between the var-
ious ErbB receptors.
The exact mechanism responsible for the down regu-
lation in the total levels of ErbB2-4 receptors following
combination treatment of g-tocotrienol with erlotinib or
gefitinib is unclear. Recent reports have shown that acti-
vated ErbB receptors can form heterodimers with other
receptor tyrosine kinases such as IGF receptors, PDGF
receptors, and c-Met, and promote breast cancer cell
growth and survival [40,41]. Therefore, it is possible that
the inhibitory growth effects observed in the combina-
tion treatment groups may also involve disrupting ErbB
receptor heterodimerization and activation of other
types of tyrosine kinase receptors.
Immunofluorescent studies revealed the presence of
ErbB1, ErbB2 and ErbB4 receptors on the plasma mem-
brane, whereas ErbB3 receptors were found in the
nucleus of neoplastic +SA mammary epithelial cells.
These findings are in agreement with previous studies
showing ErbB3 receptor localization in the nucleus [42].
The present study also showed intense phospho-ErbB4
receptor staining in the nucleus in addition to plasma
membrane even though no ErbB4 staining was observed
in the nucleus. These conflicting results can be
explained by the proteolytic cleavage of activated ErbB4
receptors and results in the formation of a soluble intra-
cellular tyrosine kinase domain. These liberated intracel-
lular domains will then undergo translocation into the
nucleus and function to regulate transcription [43,44].
The phospho-ErbB4 antibody used in the present study
detects both the intact and cleaved receptor, and
thereby visualizes immunofluorescent staining of this
form of the ErbB4 receptor in the membrane and
nucleus of +SA cells. In contrast, the antibody used to
detect total ErbB4 levels is only able to detect the intact
form of the receptor located in the cell membrane and
does not detect the cleaved form of the ErbB4 receptor.
Nevertheless, these results demonstrate that combined
treatment of g-tocotrienol with erlotinib or gefitinib
resulted in a complete inhibition in the phosphorylation
of ErbB4 receptors located on the +SA cell membrane,
but had little or no effect on nuclear phospho-ErbB4
receptors levels, and strongly suggests that the growth
inhibitory effects of combination treatment are mediated
through the attenuation of membrane ErbB4 receptor
mitogenic signaling, rather than nuclear ErbB4 receptor
modulation of transcription.
Conclusions
Clinical use of agents that target only one member of
the ErbB family of receptors have shown limited success
in the treatment of cancer. However, results in the pre-
sent study show that low-dose combination treatment
targeting multiple ErbB receptors is more effective in
inhibiting mammary tumor cell growth and inducing
apoptosis than high dose monotherapy that targets only
a single ErbB receptor subtype. These findings strongly
suggest that combination therapy may greatly improve
therapeutic responsiveness in breast cancer patients.
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